"My mother died from Alzheimer's. My sister was diagnosed 18 months ago. This isn't a research interest — it's a race against the clock I can hear ticking in every phone call home."
Founder, The Reversal Initiative
The gap between a mouse study and a human therapy isn't just biology — it's tooling. We build the open-source AI infrastructure to close that gap. Not-for-profit. Radically open.
"My mother died from Alzheimer's. My sister was diagnosed 18 months ago. This isn't a research interest — it's a race against the clock I can hear ticking in every phone call home."
Founder, The Reversal Initiative
These are real outputs from our drug discovery platform — not mockups. Interactive 3D protein structures and molecular dynamics simulations running on our infrastructure.
Every tool we build is open-source, peer-reviewed, and designed so any lab on Earth can use it — not just those with billion-dollar budgets.
AI-driven target identification across the NAD+ biosynthesis pathway. Our models evaluate binding affinity, selectivity, and blood-brain barrier penetration to prioritize the most promising intervention points.
Generative chemistry pipelines that design novel neuroprotective compounds. Each candidate is optimized for drug-likeness, synthesizability, and predicted efficacy against validated Alzheimer's mechanisms.
Multi-scale toxicity prediction before any compound reaches a living cell. Off-target binding, hepatotoxicity, cardiotoxicity, and mutagenicity are all flagged computationally — reducing animal testing and accelerating timelines.
Published in Cell Reports Medicine (2025), researchers demonstrated that the P7C3-A20 compound — an NAD+ pathway activator — reversed cognitive decline, reduced amyloid plaques, and restored synaptic function in Alzheimer's mouse models. This is the foundational biology our AI tools are built to accelerate.
Every tool we build is open-source. We publish results and cost breakdowns quarterly.
Featured at AAAI-26 Singapore — 3 oral presentations
AI for Drug Discovery workshop with peer review
Methodology validated by Stanford computational biology group
Tools actively used in commercial drug discovery pipelines
Drugs fail. Tools compound. Our research doesn't target one experiment — it builds infrastructure that every Alzheimer's researcher on Earth can use, forever.
Open-source · Free for researchers · Not-for-profit